Baseline characteristics of the EGPA cohort
| Baseline characteristics at referral | n=150 |
|---|---|
| Male | 76 |
| Age at diagnosis (years) | 49.1±1.18 |
| Months between disease onset and diagnosis | 49.7±6.1 |
| Months between manifestation of asthma and diagnosis | 111.6±10.8 |
| Five Factor Score | 1 (range 0–3) |
| Birmingham Vasculitis Activity Score | 6.0 (range 0–41) |
| Disease Extent Index | 2.5 (0–5) |
| Vasculitis Damage Index | 1 (0–5) |
| Erythrocyte Sedimentation Rate (ESR) (mm first h) | 24.4±1.89 |
| C-reactive protein (CRP) (mg/dl) | 2.5±0.77 |
| Creatine (mg/dl) | 0.9±0.02 |
| Leucocyte count (/nl) | 10.6±0.43 |
| Eosinophils (%) | 7.6±0.94 |
| Eosinophils (/nl) | 1.1±0.23 |
| ANCA+ | 45 (30%) |
| Asthma bronchiale | 139 (92.7%) |
| Blood eosinophilia >10% | 134 (89.3%) |
| Mononeuropathy or polyneuropathy | 115 (76.7%) |
| None fixed pulmonary infiltrates | 87 (58%) |
| Paranasal sinus abnormalities | 115 (76.7%) |
| Histology available | 122 (81.3%) |
| Tissue eosinophilia | 94 (63%) |
| Small vessel vasculitis | 80 (53%) |
| Extravascular granulomas | 24 (16%) |
Patients were allocated to the ANCA-positive group if at any time during the course of his disease including the time before referral a positive test was documented. Numbers are given either as mean±SD (as median and range) or as absolute number and percentage of the whole cohort.